| Bioactivity | Epetraborole (GSK2251052) is a leucyl-tRNA synthetase (LeuRS) inhibitor (IC50=0.31 μM), thereby inhibiting protein synthesis. Epetraborole can be used in multidrug-resistant gram-negative pathogens infection research[1][2][3]. |
| Target | IC50: 0.31 μM (LeuRS) |
| Invitro | Epetraborole (0-32 μg/mL) shows anti-bacterial activity against key gram-negative aerobic and anaerobic pathogens and gram-positive anaerobes[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Epetraborole 相关抗体: Cell Viability Assay[1] Cell Line: |
| CAS | 1093643-37-8 |
| Formula | C11H16BNO4 |
| Molar Mass | 237.06 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Goldstein EJ, et al. Comparative in vitro activities of GSK2251052, a novel boron-containing leucyl-tRNA synthetase inhibitor, against 916 anaerobic organisms. Antimicrob Agents Chemother. 2013 May;57(5):2401-4. [2]. O'Dwyer K, et al. Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections. Antimicrob Agents Chemother. 2015 Jan;59(1):289-98. [3]. Sutcliffe JA. Antibiotics in development targeting protein synthesis. Ann N Y Acad Sci. 2011 Dec;1241:122-52. |
Epetraborole
CAS: 1093643-37-8 F: C11H16BNO4 W: 237.06
Epetraborole (GSK2251052) is a leucyl-tRNA synthetase (LeuRS) inhibitor (IC50=0.31 μM), thereby inhibiting protein synt
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.